Mr. Mohan Uttarwar is the Founder of iNDX Technology, Inc. and serves as its Chief Executive Officer. Mr. Uttarwar serves as the Chief Strategy Advisor of Core Diagnostics Private Limited. He served as Chief Strategy Officer of BioImagene, Inc. since October 6, 2008 and its President. He was responsible for BioImagene Inc.'s strategic direction and day-to-day operations. Mr. Uttarwar has more than 25+ years of experience as a high-tech executive and entrepreneur. Mr. Uttarwar served as Chief Executive Officer of BioImagene Inc. until October 10, 2008. Prior to Co-Founding BioImagene in 2003, he Co-founded Roamware Inc. and also founded and served as President of SoftPlus. Prior to that, he Co-founded and served as President and Chief Executive Officer of Digital Tools Inc. Before Digital Tools, he held various software development and management positions at Hewlett Packard and Intel. He served as Vice Chairman and Member of the Board of Directors of Roamware Inc. He served as a Director of BioImagene, Inc. He has participated in several executive management programs at Stanford University and is a Charter Member of TiE (The Indus Entrepreneurs). He is on the board of several non-profit organizations such as IDE: a leading non-profit devoted to the eradication of rural poverty worldwide, Drev: design revolution for the other 90% and DPA: Digital Pathology Association. Mr. Uttarwar earned a Master’s Degree of Science in Computer Science from the Florida Institute of Technology and a Master's Degree of Science in Electrical Engineering from Bombay University in Mumbai. He attended Management Program at Stanford University.
Dr. Sanjay Khare
Chief Scientific Officer
Dr. Sanjay Khare is a Chief Scientific Officer at iNDx Technology. Previously Dr. Khare was President and CEO of ImmunGene since 2008. Dr. Khare has also spent almost 9 years at Amgen Inc with increasing responsibility to Scientific Director in the department of Inflammation/Immunology. While at Amgen, Dr. Khare co-discovered key immune co-stimulatory molecules such as B7RP1 and B cell activating Factor (e.g. BAFF). Dr. Khare led several drug discovery programs related to immune cell costimulation and bifunctional molecules to optimize therapeutics. Dr. Khare is co-inventor of several patents while working in Amgen and as an advisor to the start up Biotech companies. Several of these inventions have resulted in more than US$1B potential deals from large Pharmaceutical companies. Dr. Khare coauthored more than 50 scientific papers, abstracts and edited a book on TNF superfamily. Dr. Khare has successfully capitalized ImmunGene from Angel investors, VC fundings, non-profit organization (LLS) and the NIH-SBIR. Sanjay received his Ph.D. in Immunology at the All-India Institute of Medical Sciences, New Delhi, India and did his postdoctoral fellowship in the Immunology department at the Mayo Clinic and Medical School. He is a recipient of ASHI scholar award in 1997.
Dr. Gowhar Shafi
VP, Computational Biology & Translational Research
Dr. Gowhar Shafi has done his Doctorate in Medical Genetics from the Institute of Genetics & Hospital for Genetic Diseases & Dr. NTR University of Health Sciences, Hyderabad, India. He completed his postdoctoral research in Computational Medicine from Karolinska Institute, Stockholm, Sweden. Dr. Gowhar held the positions as Head Genomics/Bioinfomatics and Chief Scientific Officer at Positive Bioscience, India between 2014 and 2018. Prior to this, he worked as a junior scientist at Indo-American Cancer Hospital and Research Institute in Hyderabad, India. Dr. Gowhar has over 8 years of experience in Precision and Computational Medicine and has published more than 60 research papers in journals of international repute and has authored several book chapters on Genomics. He has extensive experience in designing and deploying data analytics tools and clinical assays. Dr. Gowhar has successfully developed and commercialised genomic tests based on next generation sequencing technology of enduring value that he was instrumental in envisioning, crafting the architecture of, doing the early R&D, prototyping.
Dr Gowhar's primary interest is in technological leadership positions that couple team-leadership with a high-octane technical hands-on involvement in machine-learning/AI models and multi-omics data sets. What distinguishes him is a technological leadership that brings together extensive, very hands-on technical ability on the one hand, and a capacity to bring together from scratch a very productive, creative, passionate and happy team across multidiscipline.
Dr Gowhar's strength is deep hands-on expertise in both wet-lab experimentations of Molecular tumor Biology, Immunology and strong data analytics capabilities including state-of-the-art in machine-learning/data-mining algorithms and its application. In addition, he has experience in building corporate relationships, networking and convince potential business partners.
Dr. Neil Sankar
Chief Scientific Advisor
Dr. Sankar received his MD degree from the University of West Indies, practiced internal medicine in the United Kingdom and holds a postgraduate degree in public health from Queensland University of Technology in Australia. Between 2009 and 2013, Dr. Sankar held the position of Clinical Scientist at Genentech and between 2013 and 2014 he was Clinical Medical Director at Pharmacyclics, an AbbVie, Inc. company. Currently, Dr. Sankar is President and Chief Medical Officer of SwanBio, LLC, a business development consultancy that facilitates the translation of scientific discoveries into cancer therapeutics. Dr. Sankar has over 16 years of experience in health care management, life sciences clinical development, pipeline strategy, clinical safety, and pharmacovigilance. He has extensive experience in the application of US Food and Drug Administration regulations and the Good Clinical Practice guidelines set forth by the International Council on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. Dr. Sankar is an expert in clinical trial design, clinical safety narration and clinical study reporting. He has acted as clinical lead in numerous phase I, II and III evaluations. He is expert in providing global clinical development and regulatory strategies for therapeutic drugs and was instrumental in filing the New Drug Applications for the antibody-drug conjugate Kadcyla and the B cell receptor signaling kinase inhibitor Ibrutinib. Dr. Sankar has extensive experience in designing and deploying data capture tools that evaluate the efficacy and safety of clinical trials. He also has extensive experience as a member of drug safety committees and advisory boards. Dr. Sankar is an active member of the American Society of Clinical Oncology, the American Society of Hematology, the European Hematology Association, Develop Innovate Advance, the Society of Clinical Research Associates, Enterprising Pharmaceutical Professionals from the Indian Sub-Continent, Connective Tissue Oncology Society, and TiE Silicon Valley. With Develop Innovate Advance, Dr. Sankar serves on the committees of Clinical Trial Design, Safety and Pharmacovigilance and Clinical Development Strategy.